Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Drug Discov Today. 2014 Sep 27;20(1):105–113. doi: 10.1016/j.drudis.2014.09.015

Figure 2.

Figure 2

The discovery of orally bioavailable signal transducers and activators of transcription 3 (STAT3) inhibitor HJC0123 by utilizing a deconstruction–reconstruction approach. (A) Deconstruction of known STAT3 inhibitors to identify privileged fragments. (B) Reconstruction of novel STAT3 inhibitors. (C) The predicted binding mode of HJC0123 to the STAT3 SH2 domain. (D) In vivo efficacy of HJC0123 in inhibiting growth of xenograft tumors in mice (p.o.). Reproduced, with permission, from [49].